HDAC9 and acute myeloid leukemia: A CMap analysis accurately identified targeted inhibitors known to have specific effects on AML, including a BCL inhibitor (ABT‐737),48 FLT3 inhibitor (TG‐101348),49 ATPase inhibitor,50 HDAC inhibitor (droxinostat),51 and CDK inhibitor (indirubin).52